Alveolar macrophages from EVALI patients and e-cigarette users: a story of shifting phenotype
-
Published:2023-06-17
Issue:1
Volume:24
Page:
-
ISSN:1465-993X
-
Container-title:Respiratory Research
-
language:en
-
Short-container-title:Respir Res
Author:
Warren Kristi J.,Beck Emily M.,Callahan Sean J.,Helms My N.,Middleton Elizabeth,Maddock Sean,Carr Jason R.,Harris Dixie,Blagev Denitza P.,Lanspa Michael J.,Brown Samuel M.,Paine Robert
Abstract
AbstractExposure to e-cigarette vapors alters important biologic processes including phagocytosis, lipid metabolism, and cytokine activity in the airways and alveolar spaces. Little is known about the biologic mechanisms underpinning the conversion to e-cigarette, or vaping, product use-associated lung injury (EVALI) from normal e-cigarette use in otherwise healthy individuals. We compared cell populations and inflammatory immune populations from bronchoalveolar lavage fluid in individuals with EVALI to e-cigarette users without respiratory disease and healthy controls and found that e-cigarette users with EVALI demonstrate a neutrophilic inflammation with alveolar macrophages skewed towards inflammatory (M1) phenotype and cytokine profile. Comparatively, e-cigarette users without EVALI demonstrate lower inflammatory cytokine production and express features associated with a reparative (M2) phenotype. These data indicate macrophage-specific changes are occurring in e-cigarette users who develop EVALI.
Funder
U.S. Department of Veterans Affairs National Institutes of Health
Publisher
Springer Science and Business Media LLC
Reference43 articles.
1. Siegel DA, Jatlaoui TC, Koumans EH, Kiernan EA, Layer M, Cates JE, Kimball A, Weissman DN, Petersen EE, Reagan-Steiner S, Godfred-Cato S, Moulia D, Moritz E, Lehnert JD, Mitchko J, London J, Zaki SR, King BA, Jones CM, Patel A, Delman DM, Koppaka R. Lung Injury Response Clinical Working G, Lung Injury Response Epidemiology/Surveillance G. Update: Interim Guidance for Health Care Providers evaluating and caring for patients with suspected E-cigarette, or Vaping, Product Use Associated Lung Injury - United States, October 2019. MMWR Morb Mortal Wkly Rep. 2019;68:919–27. 2. Perrine CG, Pickens CM, Boehmer TK, King BA, Jones CM, DeSisto CL, Duca LM, Lekiachvili A, Kenemer B, Shamout M, Landen MG, Lynfield R, Ghinai I, Heinzerling A, Lewis N, Pray IW, Tanz LJ, Patel A, Briss PA. Lung Injury Response Epidemiology/Surveillance G. characteristics of a Multistate Outbreak of Lung Injury Associated with E-cigarette Use, or Vaping - United States, 2019. MMWR Morb Mortal Wkly Rep. 2019;68:860–4. 3. Blount BC, Karwowski MP, Shields PG, Morel-Espinosa M, Valentin-Blasini L, Gardner M, Braselton M, Brosius CR, Caron KT, Chambers D, Corstvet J, Cowan E, De Jesus VR, Espinosa P, Fernandez C, Holder C, Kuklenyik Z, Kusovschi JD, Newman C, Reis GB, Rees J, Reese C, Silva L, Seyler T, Song MA, Sosnoff C, Spitzer CR, Tevis D, Wang L, Watson C, Wewers MD, Xia B, Heitkemper DT, Ghinai I, Layden J, Briss P, King BA, Delaney LJ, Jones CM, Baldwin GT, Patel A, Meaney-Delman D, Rose D, Krishnasamy V, Barr JR, Thomas J, Pirkle JL. Lung Injury Response Laboratory Working G. vitamin E acetate in Bronchoalveolar-Lavage Fluid Associated with EVALI. N Engl J Med. 2020;382:697–705. 4. Layden JE, Ghinai I, Pray I, Kimball A, Layer M, Tenforde MW, Navon L, Hoots B, Salvatore PP, Elderbrook M, Haupt T, Kanne J, Patel MT, Saathoff-Huber L, King BA, Schier JG, Mikosz CA, Meiman J. Pulmonary illness related to E-Cigarette Use in Illinois and Wisconsin - Final Report. N Engl J Med. 2020;382:903–16. 5. Prevention CfDCa. Outbreak of Lung Injury Associated with the Use of E-Cigarette, or Vaping, Products. 2021 August 3, 2021 [cited 2022 September 12, 2022]. Available from: https://www.cdc.gov/tobacco/basic_information/e-cigarettes/severe-lung-disease.html.
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
|
|